3D Bioprinting Market

3D Bioprinting Market Overview

3D printing has garnered significant attention within the healthcare industry. The concept of 3D bioprinting was conceived in the late 1990s; since then, various industry stakeholders and academicians have undertaken several initiatives in order to further develop / improve this technology for a variety of applications. Organovo was the first company to enter the 3D bioprinting space by printing functional blood vessels in 2010. The company now offers 3D printed kidney and liver tissue models. There have been a number of other notable attempts to create fully functional 3D bioprinted tissues. For instance, in 2015, 3D Bioprinting Solutions became the first company to print and transplant a thyroid gland in a mouse. Subsequently, in the same year, Aspect Biosystems developed and commercialized 3D printed human respiratory tissue for clinical testing. In addition to these, other companies with commercialized tissue products include MEDPRIN, Poietis, and Nano3D Biosciences.

The current applications of 3D bioprinted products cater to various requirements within the pharmaceutical industry for clinical testing of therapeutic drugs. Owing to the evident interspecies differences, drug candidates that are shown to be efficacious in animal models often fail in humans. For such purposes, 3D bioprinting can be used to develop more accurate, human specific disease models. Further, there is a severe unmet need when it comes to organ transplants. Therefore, the ability to synthetically create organs for transplantation purposes is expected to generate a lot of interest amongst pharmaceutical / biotechnology players in the coming years.

The current market landscape of 3D bioprinting is characterized by the presence of nearly equal number of industry and non-industry players, featuring a number of startups and university spin-offs. Although there are several 3D bioprinting technologies already available, active efforts are being made to add to the intellectual property portfolio. The field has witnessed growing partnering activity and has also managed to capture the interest of both public and private sector investors.Despite certain challenges, several technical advancements and high unmet need of current patients waiting for organ transplants is anticipated to significantly drive future growth.

Recent Developments in 3D Bioprinting Market:

Several recent developments have taken place in the field of 3D bioprinting. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In February 2023, 3D Systems entered into a strategic partnership with Regenerative Tissue Program (RPT) to develop and commercialize bioprinted human tissue by building 3D Systems expertise in Healthcare. 
• In January 2023, Sartorius announced the acquisition of 10% stake in 3D bioprinting from BICO. Additionally, the company aims to work together on R&D initiatives and come up with digital solutions for cell line development.

Scope of Report

The ‘3D Bioprinting: Technologies, Products and Key Application Areas, (2^nd Edition), 2018-2035’ report providesa comprehensive study on the current market landscape of the 3D bioprinting industry, featuring an elaborate discussion on the future potential of this evolving market. The field has seen the emergence of many new players in the past few years; in fact, several well-known players of the 3D printing industry have broadened their focus to launch new initiatives specific to 3D bioprinting. Amongst other things, the report features:

• A detailed overview of the current market landscape of 3D bioprinters and 3D bioprinted products, highlighting the contributions of industry and non-industry players, including information on the various technological aspects and key specifications of such technologies / products.
• Profiles of developers of bioprinting devices / technologies and bioprinted products. Each profile includes an overview of the company, information on their financials (wherever available), details on their respective product portfolios, 3D bioprinting specific collaborations, and an informed future outlook.
• A comprehensive product competitiveness analysis of existing 3D bioprinters, based on supplier power and product specific features such as type of technology and range of applications.
• An analysis of the partnerships that have been established in the recent past, covering research agreements, distribution agreements, product development agreements and other relevant deals, along with information on the collaborators / partners.
• An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings received by companies that are focused in this area.
• An analysis depicting the prevalent and emerging trends in 3D bioprinting as observed on the social media platform, Twitter. The report also includes a detailed case study on the upcoming trends, such as use of stem cells as bioinks, emergence of the concept of 4D bioprinting and commercialization of low-cost bioprinters, based on inputs from primary and secondary research.
• An analysis of intellectual property portfolio related to 3D bioprinting. The study presents a high-level view on the granted patents and submitted patent applications related to these technologies, highlighting the prevalent trends in this domain. In addition, the analysis highlights the most active geographies and the key players driving innovation in this field.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on various parameters, such as target consumer segments, expected adoption rates and pricing, we have provided an informed estimate of the likely evolution of the opportunity within the market in the short to mid-term and long term, for the period 2018-2035. To account for the uncertainties associated with the development of 3D bioprinted products and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The study includes detailed transcripts of discussions held with Douglas Chrisey (Professor, Tulane University), Lisa Oliver (Doctor, University of Nantes) and Fanny Geraldo (Engineer, University of Nantes), Glauco R. Souza (President and Chief Scientific Officer, n3D Biosciences), Igor Zlatkin (Application Scientist, Digilab), Kenneth Church (President and Chief Executive Officer, nScrypt) and Xudong Chen (Executive Vice President Business Development & Sales, nScrypt), Laura Bosworth (Chief Executive Officer and Co-founder, TeVido BioDevices), Lauralyn McDaniel (Industry Manager, SME), Marc Thurner (Chief Executive Officer, regenHU), Roger Narayan (Professor, North Carolina State University) and Simon Fried (Chief Business Officer, Nano Dimension). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.